Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | POLG | P54098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590058 | 1.00 | DNMT1 (0.36) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL18573362 | 1.00 | DNMT1 (0.36) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL24291985 | 0.91 | DNMT1 (0.35) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL12087580 | 0.90 | ALB (0.38) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL12015121 | 0.90 | ALB (0.38) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL67563 | 0.90 | ALB (0.38) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL22758328 | 0.89 | DNMT1 (0.35) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL24517423 | 0.89 | RNASE1 (0.46) | DNMT1ADRB1RNASE1TK1ALB | |
| SCHEMBL21227129 | 0.88 | DNMT1 (0.40) | DNMT1ADRB1ALBPOLG | |
| SCHEMBL14555941 | 0.88 | DNMT1 (0.38) | DNMT1ADRB1ALBPOLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | SOMALOGIC OPERATING CO., INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20180187197-A1 | Multiaptamer Target Detection | SOMALOGIC OPERATING CO., INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180016581-A1 | NUCLEIC ACID COMPOUNDS FOR BINDING GROWTH DIFFERENTIATION FACTOR 8 | SOMALOGIC, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20160348112-A1 | Compositions and Methods for Detecting Microorganisms | SOMALOGIC OPERATING CO. INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160324927-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING, MODULATING AND MONITORING DRUG TARGETS IN MUSCULAR DISEASE | SOMALOGIC, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20150031585-A1 | Multiaptamer Target Detection | SOMALOGIC, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8129106-B2 | Sequence-specific detection of methylation in biomolecules | Max-Planck-Geselischaft zur Forderung der Wissenschaften E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324927-A1 | COMPOSITIONS AND METHODS FOR IDENTIFYING, MODULATING AND MONITORING DRUG TARGETS IN MUSCULAR DISEASE | SMN1; SMN2, MUSK, UTRN | DNMT1 783/4885ADRB1 852/4885RNASE1 81/4885 |
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | MSTN, S100A11, IGF2BP1 | DNMT1 1236/4885ADRB1 4051/4885RNASE1 370/4885 |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | DNMT1, MAT2B, AHCY | DNMT1 1/4885ADRB1 3648/4885RNASE1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.